Case no
|
Age/sex
|
Colonic carcinoma
|
Extra-colonic malignancy
|
---|
TNM staging
|
Site
|
TNM staging
|
---|
Colonic carcinoma
|
1
|
68/F
|
T4a
|
N1b
|
M0
|
IIIB
|
Renal
|
T1a
|
N0
|
M0
|
I
|
2
|
68/M
|
T4a
|
N1b
|
M0
|
IIIB
|
Renal
|
T1b
|
N0
|
M0
|
I
|
3
|
58/M
|
T4a
|
N2b
|
M0
|
IIIC
|
Renal
|
T1a
|
N0
|
M0
|
I
|
4
|
65/F
|
T3
|
N1a
|
M0
|
IIIB
|
Renal
|
T1a
|
N0
|
M0
|
I
|
5
|
67/M
|
T4a
|
N2a
|
M0
|
IIIC
|
Renal
|
T1b
|
N0
|
M0
|
I
|
6
|
54/F
|
T4a
|
N2b
|
M0
|
IIIB
|
Breast
|
T2
|
N0
|
M0
|
IIA
|
7
|
65/F
|
T4a
|
N2b
|
M1C
|
IVC
|
Breast
|
T2
|
N0
|
M0
|
IIA
|
8
|
60/F
|
T4b
|
N0
|
M0
|
IIC
|
Breast
|
Recurrent metastatic breast cancer
|
9
|
65/F
|
T4a
|
N0
|
M0
|
IIB
|
HCC
|
A (BCLC staging)
|
10
|
66/M
|
T3
|
N1
|
M0
|
IIIB
|
HCC
|
C (BCLC staging)
|
11
|
64/F
|
T4b
|
N1
|
M0
|
IIIC
|
HCC
|
C (BCLC staging)
|
12
|
76/M
|
T3
|
N2a
|
M0
|
IIIB
|
Prostate
|
T3a
|
N0
|
M0
|
IIIB
|
13
|
82/M
|
T3
|
N0
|
M0
|
IIA
|
Prostate
|
T2c
|
N0
|
M0
|
IIC
|
14
|
71/M
|
T4a
|
N0
|
M0
|
IIB
|
Prostate
|
T2c
|
N0
|
M0
|
IIC
|
15
|
52/M
|
T3
|
N2a
|
M0
|
IIIB
|
UB
|
T3b
|
N0
|
M0
|
IIIA
|
16
|
74/M
|
T3
|
N0
|
M0
|
IIA
|
UB
|
T3b
|
N0
|
M0
|
IIIA
|
17
|
52/F
|
T3
|
N2a
|
M1a
|
IVA
|
Ovarian
|
Local recurrent
|
18
|
65/F
|
T3
|
N2a
|
M1a
|
IVA
|
Ovarian
|
I (FIGO staging)
|
19
|
53/F
|
T4a
|
N0
|
M0
|
IIB
|
Endo
|
IB (FIGO staging)
|
20
|
66/F
|
T4a
|
N1
|
M0
|
IIIB
|
Endo
|
IIIC1 (FIGO staging)
|
21
|
69/M
|
T4a
|
N1
|
M1a
|
IVA
|
NHL
|
III (Ann Arbor Staging)
|
22
|
60/F
|
T2
|
N2a
|
M0
|
IIIB
|
HD
|
II (Ann Arbor Staging)
|
23
|
68/M
|
T4a
|
N2a
|
M0
|
IIIC
|
Thyroid
|
T3a
|
N1b
|
M0
|
II
|
24
|
66/F
|
T3
|
N0
|
M0
|
IIA
|
Lung
|
T1c
|
N2
|
M0
|
IIIA
|
|
Age/sex
|
Stomach
|
Extra-gastric malignancy
|
---|
TNM staging
|
Site
|
TNM staging
|
---|
Gastric carcinoma
|
25
|
65/F
|
T3
|
N0
|
M0
|
IIA
|
HCC
|
B (BCLC staging)
|
26
|
66/F
|
T3
|
N3
|
M1
|
IV
|
Breast
|
T4b
|
N2a
|
M0
|
IIIB
|
27
|
75/F
|
T3
|
N2
|
M0
|
IIB
|
Breast
|
T3
|
N1
|
M0
|
IIIA
|
28
|
66/F
|
T4a
|
N3a
|
M0
|
IIIC
|
NHL
|
II (Ann Arbor Staging)
|
29
|
58/M
|
T3
|
N0
|
M0
|
IIA
|
HD
|
I (Ann Arbor Staging)
|
30
|
60/F
|
T3
|
N0
|
M1
|
IV
|
Endo
|
Ib (FIGO staging)
|
|
Age/sex
|
Periampullary
|
Extra-periampullary malignancy
|
---|
TNM staging
|
Site
|
TNM staging
|
---|
T
|
N
|
M
|
Stage
| |
T
|
N
|
M
|
Stage
|
---|
Carcinoma
|
31
|
65/F
|
T3b
|
N0
|
M0
|
IIB
|
UB
|
T2b
|
N0
|
M0
|
II
|
32
|
80/M
|
T3b
|
N0
|
M0
|
IIB
|
UB
|
T3b
|
N0
|
M0
|
IIIA
|
33
|
74/M
|
T1
|
N0
|
M0
|
IA
|
Renal
|
T1a
|
N0
|
M0
|
I
|
|
Neuroendocrine
|
34
|
64/F
|
T2
|
N0
|
M0
|
II
|
Breast
|
T4b
|
N2a
|
M0
|
IIIA
|
- BCLC: Barcelona Clinic Liver Cancer staging classification, Endo.: Endometrial carcinoma, FIGO: the International Federation of Gynecology and Obstetrics, HCC: hepatocellular carcinoma, HD: Hodgkin disease, NHL: Non-Hodgkin lymphoma, RCC: renal cell carcinoma, UB: urinary bladder